IBI362

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 DiabetesObesityHepatitisObstructive Sleep ApneaWeight LossFatty Liver Disease

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

1

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

42

NOVOLIN R

Novo Nordisk

Preclinical

53

Cysteine Hydrochloride

Novartis

Preclinical

14

Aurlumyn

BBTG International Inc.

Preclinical

15

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

16

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

17

Forxiga

AstraZeneca

Preclinical

38

Lovaza

AstraZeneca

Preclinical

19

Acipimox

Boehringer Ingelheim

Preclinical

210

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity4 trials

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

Recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT06862908·141 enrolled

This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT06536023·36 enrolled

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Active, not recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT07000955·98 enrolled

Show 1 more trial

A Study of IBI362 9 mg in Chinese Adults With Obesity

Active, not recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06164873·462 enrolled

Type 2 Diabetes4 trials

A Study of IBI362 in Participants With Type 2 Diabetes

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT05606913·731 enrolled

A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT05628311·319 enrolled

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Active, not recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06184568·349 enrolled

Show 1 more trial

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT04965506·252 enrolled

Overweight4 trials

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Not yet recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT07469800·336 enrolled

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

Recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT07255209·180 enrolled

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04440345·60 enrolled

Show 1 more trial

A Study of IBI362 in Participants With Obesity or Overweight

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT05607680·610 enrolled

Overweight or Obese1 trial

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05815680·48 enrolled

Weight loss1 trial

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT04904913·328 enrolled

6 more indications

T2DM1 trial

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04466904·42 enrolled

Hepatitis1 trial

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT06937749·165 enrolled

Fatty Liver Disease1 trial

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

Recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06884293·470 enrolled

Obstructive Sleep Apnea1 trial

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

Recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06931028·260 enrolled

Renal Impairment1 trial

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05793450·20 enrolled

Unspecified1 trial

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04773977·24 enrolled

Details

Drug Info

Related News